Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety of two propellant components used in metered dose inhalers MDIs for people with asthma. The study compares a newer propellant called HFA-152a with the commonly used HFA-134a to gather more safety information. This is a Phase 3 randomized study designed to evaluate these propellants when delivered via inhalers. Participants will receive both propellants in two separate treatment periods in a crossover design. Some will use HFA-152a first followed by HFA-134a, while others will receive them in the reverse order. A washout period occurs between the two treatment phases to clear the first propellant before starting the second. During the study, participants will be closely monitored for any adverse events up to 8 weeks. Vital signs such as blood pressure, pulse rate, heart rate, and ECG readings will be measured at specific times. Researchers will assess safety by looking at changes from baseline and any serious side effects. The total participation length covers both treatment periods and follow-up assessments.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.